ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

QLGN Qualigen Therapeutics Inc

0.2905
-0.0065 (-2.19%)
27 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Qualigen Therapeutics Inc NASDAQ:QLGN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.0065 -2.19% 0.2905 0.2777 0.30 0.319 0.2905 0.30 9,247 01:00:00

Initial Statement of Beneficial Ownership (3)

17/05/2021 9:26pm

Edgar (US Regulatory)


FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

ARSHAD TARIQ
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/17/2021 

3. Issuer Name and Ticker or Trading Symbol

Qualigen Therapeutics, Inc. [QLGN]
(Last)        (First)        (Middle)

C/O QUALIGEN THERAPEUTICS, INC.,, 2042 CORTE DEL NOGAL, SUITE B
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                          _____ 10% Owner
___X___ Officer (give title below)        _____ Other (specify below)
SVP/Chief Medical Officer /
(Street)

CARLSBAD, CA 92011      

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed(MM/DD/YYYY)
 

6. Individual or Joint/Group Filing(Check Applicable Line)

_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:

Remarks:
Exhibit List - Exhibit 24 - Power of Attorney
No securities are beneficially owned.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
ARSHAD TARIQ
C/O QUALIGEN THERAPEUTICS, INC.,
2042 CORTE DEL NOGAL, SUITE B
CARLSBAD, CA 92011


SVP/Chief Medical Officer

Signatures
/s/ Hayden Trubitt, Attorney-in-Fact for Tariq Arshad5/17/2021
**Signature of Reporting PersonDate

1 Year Qualigen Therapeutics Chart

1 Year Qualigen Therapeutics Chart

1 Month Qualigen Therapeutics Chart

1 Month Qualigen Therapeutics Chart

Your Recent History

Delayed Upgrade Clock